19:57:14 EDT Tue 30 Apr 2024
Enter Symbol
or Name
USA
CA



Zentek Ltd
Symbol ZEN
Shares Issued 100,859,577
Close 2023-12-12 C$ 1.45
Market Cap C$ 146,246,387
Recent Sedar Documents

Zentek launches subsidiary Triera for aptamer tech

2023-12-13 15:46 ET - News Release

Mr. Greg Fenton reports

ZENTEK LAUNCHES TRIERA BIOSCIENCES LTD.

Zentek Ltd. has launched Triera Biosciences Ltd. as Zentek's wholly owned subsidiary for its aptamer platform technology. As announced in the Oct. 5, 2023, news release, this subsidiary now owns the exclusive, global licensing rights for all aptamer-based technology from the collaboration with McMaster University.

The company is taking this action following the strong, consistent preclinical results of its universal aptamer as a treatment against the SARS-CoV-2 virus, including the latest Omicron XBB 1.5 variant, and will continue to build upon its previous work on a rapid detection platform within the new subsidiary. Triera will offer a pure play in the biotech space when operated as an independent business and be more accessible to potential pharmaceutical partners, financiers and other interested parties.

"The aptamer platform technology has quickly evolved into a strong differentiated value creator for Zentek and its investors. By launching Triera Biosciences, we are creating a standalone company with a clear, concise, differentiated value proposition that will appeal directly to the biotech ecosystem," said Greg Fenton, chief executive officer of Zentek. "With the launch of Triera we have begun outreach to potential partners and collaborators as we continue to build on our current preclinical results and develop our team."

The company is launching a new website where investors and stakeholders can review the latest developments of the aptamer platform technology.

The company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time.

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer and greener.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.